Elite Pharmaceuticals Q1 FY27 operating income drops 65% to $7.5 million; revenue falls 20% to $32.4 million
ELTP•Product and filing updates
- Launched generic methadone tablets in April 2026.
- Filed an ANDA for an undisclosed anticoagulant in June 2026.
Quarterly financial results
Elite Pharmaceuticals Q1 results: revenue fell 20% to $32.36 million, while net income was $5.9 million.
- Gross profit dropped 50% to $13.51 million; gross margin narrowed 26 percentage points to 42%.
- Operating income slid to $7.5 million from $21.7 million a year earlier.
- Research and development expense rose 21% to $2.03 million; total operating expenses increased 8% to $5.98 million.
